{"filing":{"accession_number":"0001193125-26-283906","cik":"0001798749","ticker":"JBIO","company_name":"Jade Biosciences, Inc.","form":"8-K","filing_date":"2026-06-26","report_date":null,"primary_document":"d127137d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526283906/d127137d8k.htm"},"events":[{"id":14110,"run_id":12548,"accession_number":"0001193125-26-283906","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Jade Biosciences appointed Mark Eisner, M.D., M.P.H., to its Board of Directors as a Class I director and member of the Nominating and Corporate Governance Committee, effective June 25, 2026. Dr. Eisner brings 25+ years of clinical development and immunology leadership, including prior roles as Chief Medical Officer at Vir Biotechnology and FibroGen, and 11 years at Genentech/Roche, directly supporting the company's pipeline advancement.","company_name":"Jade Biosciences, Inc.","ticker":"JBIO","filing_date":"2026-06-26","form":"8-K","submitted_at":null,"items":[{"id":11447,"accession_number":"0001193125-26-283906","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Mark Eisner, M.D., M.P.H., to serve as a Class I director and member of the Nominating and Corporate Governance Committee, effective June 25, 2026. Dr. Eisner brings substantial biopharmaceutical leadership experience, including prior roles as EVP/Chief Medical Officer at Vir Biotechnology and FibroGen, and 11 years at Genentech/Roche. The appointment is material to investors as it reflects board composition changes and the addition of experienced clinical development expertise relevant to the company's pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T11:16:40.012481+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11448,"accession_number":"0001193125-26-283906","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Mark Eisner, M.D., M.P.H., to Jade Biosciences' Board of Directors, effective June 25, 2026. The press release emphasizes his 25+ years of leadership in clinical development and immunology, including prior roles as Chief Medical Officer at multiple biopharmaceutical companies and Senior Vice President at Genentech/Roche. This is a material board appointment for a clinical-stage biotech company, as his expertise directly supports the company's pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T11:16:40.012481+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11447,"accession_number":"0001193125-26-283906","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Mark Eisner, M.D., M.P.H., to serve as a Class I director and member of the Nominating and Corporate Governance Committee, effective June 25, 2026. Dr. Eisner brings substantial biopharmaceutical leadership experience, including prior roles as EVP/Chief Medical Officer at Vir Biotechnology and FibroGen, and 11 years at Genentech/Roche. The appointment is material to investors as it reflects board composition changes and the addition of experienced clinical development expertise relevant to the company's pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T11:16:40.012481+00:00","company_name":"Jade Biosciences, Inc.","ticker":"JBIO","filing_date":"2026-06-26"},{"id":11448,"accession_number":"0001193125-26-283906","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Mark Eisner, M.D., M.P.H., to Jade Biosciences' Board of Directors, effective June 25, 2026. The press release emphasizes his 25+ years of leadership in clinical development and immunology, including prior roles as Chief Medical Officer at multiple biopharmaceutical companies and Senior Vice President at Genentech/Roche. This is a material board appointment for a clinical-stage biotech company, as his expertise directly supports the company's pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T11:16:40.012481+00:00","company_name":"Jade Biosciences, Inc.","ticker":"JBIO","filing_date":"2026-06-26"}]}